Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1 antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer patients, in order to find a better therapy strategy for pancreatic cancer patients.
Anlotinib|Anti-PD-1 Antibody|Advanced Pancreatic Cancer
DRUG: Anlotinib plus AK105
Disease control rate (DCR) based on RECIST v. 1 1, Disease control rate (DCR) based on RECIST v. 1 1 by investigators, 6 weeks
Objective response rate (ORR) based on RECIST V. 1.1, Objective response rate (ORR) based on RECIST V. 1.1 by investigators, 6 weeks|Progression free survival (PFS) measured from the date of anlotinib plus AK105 initiation to the time of progression, Progression free survival (PFS) measured from the date of anlotinib plus AK105 initiation to the time of progression by investigators assessment, 6 weeks|Overall survival (OS) measured from the date of anlotinib plus AK105 initiation to the time of death of any cause, Overall survival (OS) measured from the date of anlotinib plus AK105 initiation to the time of death of any cause by investigators assessment, 6 weeks|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, adverse events assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0)., 6 weeks
This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1 antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer patients, in order to find a better therapy strategy for pancreatic cancer patients.